[A21-83] Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2021
Project no.:
A21-83
Commission:
Commission awarded on 15.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Indication:
Adult patients with relapsing forms of multiple sclerosis (RMS)
Result of dossier assessment:
- Adults with RMS who have not yet received disease-modifying therapy or adult patients with non-highly active disease pretreated with disease-modifying therapy: added benefit not proven.
- Adults with RMS with highly active disease despite treatment with disease-modifying therapy: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-159 | Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |